Ainuovirine Tablets Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is an HIV-1 non-nucleoside reverse transcriptase inhibitor supplied as a pharmaceutical-grade active pharmaceutical ingredient under current good manufacturing practice controls aligned with ICH Q7, 21 CFR 210, and 21 CFR 211. The grade does not carry a separate promotional model number; the product code and batch designation are assigned in the supplier’s certificate of analysis and drug master file. Each lot is released against a specification covering appearance, identification, assay, related substances, residual solvents, water content, residue on ignition, particle-size distribution, and, for the injectable grade, bacterial endotoxins and bioburden. No public monograph in the European Pharmacopoeia or United States Pharmacopeia was identified for ainuovirine at the time of writing; the analytical framework therefore follows ICH Q6A decision trees and validated in-house methods. The registered therapeutic use is the treatment of HIV-1 infection in combination with other antiretroviral agents, with the API intended for further manufacture of film-coated tablets, hard capsules, granules for reconstitution or direct administration, and injectable products. The oral and injectable grades are separated by particle cleanliness, microbial quality, and endotoxin control, not by a change in the active molecular entity.

Direct compression of oral-grade Ainuovirine requires particle-size and flow control.

Direct compression of ainuovirine tablet blends is governed by bulk density, tapped density, and flow function coefficient rather than by chemical assay alone. Powder flow is characterised according to USP <1174>, with bulk and tapped density determined by USP <616>; the resulting Hausner ratio and compressibility index are used to establish whether dry blending can feed a high-speed rotary tablet press without segregation. Experience on production lines indicates that low-density API lots with a high fines fraction can cause feed-frame binding, die-fill variability, and tablet weight fluctuation if the turret speed exceeds the flow capability of the blend.

For a poorly water-soluble NNRTI, particle-size reduction is typically performed by jet milling or pin milling; the target D90 is lot-specific and documented in the drug master file. Published data for the ainuovirine-specific micronisation target is limited, and processors should confirm the D90 by laser diffraction using ISO 13320 before committing to direct compression. Tablet press compatibility should be evaluated on a rotary press with compaction force capacity up to 100 kN and a turret speed range consistent with the intended commercial output. Compression trials should monitor ejection force, punch sticking, and friability in accordance with USP <1216> and USP <1217>.

Pre-drying of API or dry granulation may be required if residual moisture exceeds the documented limit for the specific lot. For comparable APIs, pre-drying at residual moisture ≤2.0% w/w before blending reduces the risk of punch filming and picking on a high-speed press; however, ainuovirine-specific stability and hydration data from the drug master file should override generic limits. The formulation differences from efavirenz- and nevirapine-based tablets are not limited to chemistry; they shift the mechanical inter-particulate bonding and the sensitivity to magnesium stearate overlubrication, which must be characterised by compaction simulator or instrumented rotary press studies.

In low-dose capsule manufacturing, where the drug load per unit may fall below 10 mg, content uniformity is governed by the API particle-size distribution, blend segregation, and the shear history applied in tumble mixing. A tamping-pin capsule filler or dosator system must be selected after evaluating the blend bulk density and flow. Filling of ainuovirine capsules should follow USP <905> uniformity of dosage units and USP <1174> powder flow. Batch records from similar poorly water-soluble NNRTI capsule operations show that delumping of API through a 500-µm screen after pre-mixing reduces aggregate carryover and improves content uniformity when the API content is less than 10% w/w. Capsule fill weight and plug height are adjusted on the basis of machine vendor specifications and the compressibility of the powder bed; a fixed fill volume without bulk-density compensation can produce unacceptable weight variation if incoming API bulk density varies by more than ±10% relative to the qualification lot. The shell composition should be evaluated for moisture permeability because a low-dose hydrophobic API can adhere to the shell wall in humid environments; storage at 25 °C and 60% RH follows ICH Q1A stability protocols.

When ainuovirine is specified as an injectable-grade API, what specification changes apply to the oral grade?

Injectable formulation requires the removal of the oral-grade particle-size and flow assumptions. The API must meet low bioburden and bacterial endotoxin limits specified in the pharmacopoeial framework; bacterial endotoxin is tested by Ph. Eur. 2.6.14 or USP <85>, and the final dosage form must comply with USP <788> particulate matter limits for injections. The manufacturing environment for injectable API handling is classified according to ISO 14644-1; open processing is conducted in areas meeting the appropriate cleanroom class for the process step, with terminal sterilisation or aseptic filtration after product formulation.

Solubilisation of ainuovirine for injectable products is a critical process conflict. If the API exists as a crystalline powder with low aqueous solubility, direct dissolution into water for injection is unlikely to produce a sufficiently concentrated formulation without a pH adjustment or a co-solvent system. Published data for the ainuovirine-specific aqueous solubility is limited in public sources; formulation development should determine thermodynamic solubility under ICH Q6A pH-buffer conditions and report the result in the pharmaceutical development section of the registration file. Filtration compatibility studies should include polyethersulfone and polyvinylidene difluoride membranes because hydrophobic APIs can adsorb to filter surfaces; membrane surface area, filter pore size, and flow rate are specified in the filter vendor technical bulletins. If the injectable grade is intended for terminal sterilisation, the thermal stability and hydrolytic degradation profile of ainuovirine should be verified at the proposed sterilisation temperature and hold time; unsuitable combinations with alkaline buffer systems should be assessed before scale-up.

Comparative specification matrix for oral and injectable Ainuovirine API grades

The differentiation between grades is therefore procedural and specification-based rather than synthetic. A single synthesis may produce material suitable for both routes provided the final crystallisation and milling steps do not introduce particulate contamination or excessive fines.

Compared with efavirenz, nevirapine, and rilpivirine, ainuovirine differs in its diarylpyrimidine substitution pattern, which is described in the registration dossier as modifying the binding mode to the HIV-1 reverse transcriptase hydrophobic pocket. The manufacturing consequence is that the API does not inherit the same crystallinity, bulk density, or compression defect profile as efavirenz or nevirapine. Efavirenz tablets often require a high-shear granulation step to overcome poor compressibility and sticking; nevirapine tablets require careful control of polymorphic form. Ainuovirine formulation development therefore cannot rely on legacy efavirenz or nevirapine master process parameters without a new compaction simulation.

If high-shear granulation substitutes for direct compression, process-parameter boundaries must be redefined

High-shear wet granulation remains the preferred route when direct compression cannot achieve the required tablet hardness or drug-load uniformity. In a top-driven high-shear granulator, the impeller speed, chopper speed, binder solution addition rate, and wet mass time are mutually dependent; for comparable poorly water-soluble APIs, an impeller tip speed of 3–8 m/s and a water addition rate not exceeding 5% w/w per minute are typical starting values, but ainuovirine-specific rheological data should be generated on the actual granulator geometry. The endpoint is commonly determined by impeller power consumption or torque, not by fixed time alone. If the granulate is over-wetted, the subsequent drying step may produce dense granules with reduced tablet porosity and slower dissolution; if under-wetted, the granulate may generate fines that cause tablet capping.

Drying of granules should follow ICH Q1A stability stressors and should not exceed the maximum product temperature defined in the drug master file for ainuovirine. A fluid-bed dryer with inlet air temperature 50–65 °C and product temperature 30–40 °C is a common starting point for comparable compounds, but the actual window depends on the solvent composition and the thermal stability of the drug substance. Milling of dried granules through a 1.0-mm screen using a cone mill or oscillating granulator is used to break oversized agglomerates. The milled granule is then lubricated with magnesium stearate at 0.5–1.5% w/w; excessive lubrication can reduce tablet breaking force by forming a hydrophobic film over the granule surfaces, while insufficient lubrication can cause ejection force increases and tablet tooling wear on a rotary press. Each compression run should be controlled by in-process checks for weight, hardness, thickness, and friability under USP <1216> and USP <1217>.

For injection-grade manufacturing, the API is typically processed in a segregated area with filtration and filling equipment qualified under ISO 14644-1 class for aseptic processing. The main process conflict is not blend flow but sterile filtration capacity. Hydrophilic filter membrane compatibility and adsorption losses should be evaluated before scale-up; a filter surface area to volume ratio is selected based on filter vendor data, not by visual clarity alone. The final injectable product must meet USP <788> for subvisible particulates and USP <790> for visible particulates, and the container-closure integrity should be confirmed by dye ingress or vacuum decay according to USP <1207>. If the product is a lyophilised injectable, the cake structure and reconstitution time are determined by the formulation matrix and the freezing rate; a collapsed cake can result from primary drying above the collapse temperature. Ainuovirine-specific thermal and collapse data should be obtained from differential scanning calorimetry and freeze-drying microscopy before cycle scaling.